Celularity (CELU)
Develops placenta-derived cell therapies for longevity and age-related disease.
Something off on this page? Send us feedback.
Develops and manufactures allogeneic and autologous cell therapies derived from postpartum placenta. It refocused on longevity and cell-therapy platforms after out-licensing its biomaterials portfolio.
Develops and manufactures allogeneic and autologous cell therapies derived from postpartum placenta, with a current focus on longevity and cell-therapy platforms. Its development portfolio includes MLASC candidates PDA-001 and PDA-002, plus the CYNK-001 and CYNK-101 natural-killer-cell platforms.
Those programs address Crohn’s disease, diabetic foot ulcer, facioscapulohumeral muscular dystrophy, solid tumors, autoimmune disease, and cancer combinations. Placental T-cell work includes allogeneic cells with CAR expression and knockout of endogenous T-cell receptors.
Headquartered in Florham Park, New Jersey, the company out-licensed its biomaterials portfolio to concentrate resources on cell therapy and longevity. Its development model depends on postpartum placenta as an ethically sourced, scalable biological input; the named programs are development platforms, not approved therapies.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2025 | WBB Securities | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $6.2M · Total debt $40.9M · Total assets $107.3M · Shareholders' equity −$38.1M
- Revenue
- $4.1M
- Operating income
- −$22.1M
- Net income
- −$24.4M
No dividends on record.
| Institutions | 7.77% | 2.20M shares | |
|---|---|---|---|
| 41 holders · as of Jun 30, 2026 | |||
| Insiders | 89.40% | 25.32M shares | |
| 12 holders · as of Apr 15, 2026 | |||
| Strategic holders | 0.56% | 158.4K shares | |
| 1 holder · as of Jun 1, 2021 | |||
| Other | 2.27% | 644.3K shares | |
| remainder | |||
28.33M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kok Thay Lim1Insider10 percent owner | 72.27% | 14.14M · 6.34M | filed Jul 28, 2025 |
Robert J. HaririInsiderdirector, officer: Chief Executive Officer | 10.07% | 2.85M | filed Apr 15, 2026 |
C V Starr & Co IncInstitution | 2.70% | 764,069 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.19% | 621,105 | as of Jun 30, 2026 |
Diane L. ParksInsiderdirector | 1.84% | 520,021 | filed Jan 14, 2026 |
- Kok Thay Lim's transaction reports restate only vehicles that traded; the 2025 ownership statement (14.14M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Pluri
Placenta-derived allogeneic stromal-cell therapies for regeneration
- Allogene Therapeutics
Off-the-shelf allogeneic CAR-T for cancer and autoimmune disease
- Fate
iPSC-derived off-the-shelf CAR-T and NK-cell programs
- Nkarta
Engineered allogeneic CAR-NK therapies for autoimmune disease
- Century Therapeutics
iPSC-derived allogeneic therapies for autoimmune disease and cancer
- Mesoblast (ADR)
Allogeneic stromal-cell medicines for inflammatory disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Celularity | $1.19 | −4.03% | $35.9M | — | — | — | −64.1% |
| Pluri | $1.04 | −2.80% | $11.5M | — | — | 11.4 | −15.8% |
| Allogene Therapeutics | $1.71 | +0.89% | $583.3M | — | — | 125.7 | — |
| Fate | $2.60 | +2.57% | $294.9M | — | — | 45.4 | +9.2% |
| Nkarta | $2.90 | +0.83% | $206.1M | — | — | — | — |
| Century Therapeutics | $1.90 | +2.70% | $160.2M | — | — | — | — |
| Mesoblast (ADR) | $15.86 | +2.45% | $2.01B | — | — | 16.6 | +391.8% |
| Median | — | — | 31.0 | +9.2% |